GlassScriptPhysician profile
Andre R Plair
NPI 1093158081
$4,853.76
in general payments reported to CMS, 2019-2025
14 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2021: $87.86 · 2022: $1,345 · 2023: $1,308 · 2024: $893 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,896 · Travel and Lodging: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,895.93 |
| Travel and Lodging | $1,399.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,550.33 | 2022-2024 | Axonics, Bulkamid |
| Medtronic, INC. | $964.11 | 2022-2025 | Altaviva, Interstim |
| Abbvie INC. | $583.31 | 2022-2025 | |
| Valencia Technologies Corporation | $577.45 | 2023 | Ecoin Device Kit |
| Caldera Medical, INC | $351.46 | 2024 | Desara |
| Boston Scientific Corporation | $261.89 | 2019-2025 | Axonics |
| Bluewind Medical | $231.07 | 2024 | Revi |
| Sumitomo Pharma America, INC. | $113.43 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $86.11 | 2019-2022 | |
| Urovant Sciences INC | $46.18 | 2022 | |
| Coloplast Corp | $31.50 | 2023 | Altis |
| Avation Medical, INC. | $25.34 | 2024 | Vivally |
| Medtronic USA, INC. | $18.21 | 2019 | |
| Allergan, INC. | $13.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Plair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.